Cargando…
Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
BACKGROUND AND OBJECTIVES: Vericiguat is a soluble guanylate cyclase stimulator indicated to reduce the risk of cardiovascular death and hospitalization due to heart failure. A dedicated QTc study in patients with chronic coronary syndromes demonstrated no clinically relevant QTc effect of vericigua...
Autores principales: | Ruehs, Hauke, Solms, Alexander, Frei, Matthias, Becker, Corina, Trujillo, Maria E., Garmann, Dirk, Meyer, Michaela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581916/ https://www.ncbi.nlm.nih.gov/pubmed/37672197 http://dx.doi.org/10.1007/s40262-023-01282-y |
Ejemplares similares
-
Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021) -
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes
por: Böttcher, Michael, et al.
Publicado: (2023) -
Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020) -
No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
por: Mu, Song, et al.
Publicado: (2020) -
The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)